Biotech Industry · global
Iambic seeks to raise $150 million to advance AI-designed HER2 cancer drug
There is still a long way to go from an algorithm proposing a molecule to demonstrating efficacy in patients. Iambic has announced the terms of its initial public offering, with its lead drug already in early human trials. The next stage will test its clinical evidence and ability to sustain funding.
Whether artificial intelligence can shorten the path of drug discovery must ultimately be answered through human trials. U.S. biotech company Iambic Therapeutics announced the terms of its initial public offering (IPO) on October 8, seeking to raise approximately $150 million to advance AI-designed small-molecule cancer drugs. Its most advanced HER2 inhibitor, IAM1363, is being evaluated in a Phase 1/1b clinical trial.
According to IPOScoop, citing the amended listing application filed that day, Iambic plans to offer approximately 9.38 million shares at a price range of $15 to $17 per share. At the midpoint of $16, the offering would raise approximately $150 million. Renaissance Capital reported that the company planned to list on Nasdaq under the ticker “IAM” and, at the time, expected to price the offering during the week of October 12. These figures represent offering plans and cannot yet be treated as completed fundraising.
The offering has already attracted preliminary indications of interest. Renaissance Capital noted that some investors had expressed interest in purchasing a combined $60 million in shares, equivalent to 40% of the planned offering, but indications of interest do not constitute completed purchases. The two outlets also used different valuation measures: IPOScoop estimated a market capitalization of approximately $758 million, while Renaissance Capital listed a fully diluted valuation of approximately $809 million. The two figures should not be used interchangeably.
Iambic uses AI to help design drug molecules that can then be synthesized and tested. According to Renaissance Capital, its platform connects models with automated chemistry and biological experiments: the models propose candidate compounds, the laboratory makes and tests them, and the resulting data are used to update the models. This cycle allows computational predictions to be continually refined through experiments. Whether it can improve drug development success rates will still require accumulated clinical results to assess.
IAM1363 is currently the main clinical test of this development approach. It is an oral small-molecule HER2 inhibitor designed to penetrate the brain, and the trial enrolls patients with solid tumors harboring HER2 alterations. HER2 is a receptor involved in cell growth signaling and an important therapeutic target in some cancers. The company says a registrational trial intended to support a marketing application could begin as early as 2027. However, this remains a development timeline, rather than confirmation of efficacy or regulatory approval for marketing.
The financial figures also illustrate the support needed for further development. According to IPOScoop, Iambic reported collaboration revenue of $18.25 million and a net loss of $94.25 million for the 12 months ended June 30, 2026. Announcing the offering terms makes the fundraising plan more concrete. However, the IPO news itself provided no new, comprehensive analysis of efficacy and safety. For these AI-designed drugs, the more consequential developments will be whether early human trials can support the next stage of development and whether subsequent studies can establish sufficient evidence for regulatory review.